Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1600-0501
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Abstract: The aim of the present study was (1) to test whether or not platelet-rich plasma (PRP) or commercially available fibrin can increase bone regeneration compared with non-treated defects and (2) to test whether or not PRP or fibrin increases bone regeneration when used as a delivery system for recombinant human bone morphogenetic protein-2 (rhBMP-2). In 16 New Zealand White rabbits, four evenly distributed 6 mm diameter defects were drilled into the calvarial bone. The following five treatment modalities were randomly allocated to all 64 defects: (0) untreated control, (1) fibrin alone, (2) PRP alone, (3) fibrin with 15 μg rhBMP-2 and (4) PRP with 15 μg rhBMP-2. For the fibrin gels and the PRP containing rhBMP-2, the 15 μg rhBMP-2 was incorporated by precipitation within the matrices before their gelation. After 4 weeks, the animals were sacrificed and the calvarial bones were removed for histological preparation. The area fraction of newly formed bone was determined in vertical sections from the middle of the defect by applying histomorphometrical analysis. A mean area fraction of newly formed bone was found within the former defect of 23.4% (±13.5%) in the control sites, of 28.4% (±17.4%) in the fibrin sites and of 34.5% (±17.4%) in the PRP sites. The statistical analysis revealed no significant difference in bone formation between the three groups (ANOVA). Addition of 15 μg rhBMP-2 in the fibrin gel (59.9±20.3%) and the PRP gels (63.1±25.3%) increased bone formation significantly. No significant difference was observed between sites, where PRP or fibrin has been used as a delivery system for rhBMP-2 (ANOVA). In conclusion, the application of fibrin gels or PRP gels to bone defects is not superior to leaving the defect untreated. Regarding the amount of bone formation, the application of 15 μg rhBMP-2 in bone defects enhances the healing significantly at 4 weeks. In this animal model, commercially available fibrin and autologous PRP gels are equally effective as delivery systems for rhBMP-2.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Oxford UK : Munksgaard International Publishers
    Periodontology 2000 33 (2003), S. 0 
    ISSN: 1600-0757
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1600-0501
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Abstract: The aim of the present clinical study was to test whether or not the addition of recombinant human bone morphogenetic protein-2 (rhBMP-2) to a xenogenic bone substitute mineral (Bio-Oss®) will improve guided bone regeneration therapy regarding bone volume, density and maturation. In 11 partially edentulous patients, 34 Brånemark implants were placed at two different sites in the same jaw (five maxillae, six mandibles) requiring lateral ridge augmentation. The bone defects were randomly assigned to test and control treatments: the test and the control defects were both augmented with the xenogenic bone substitute and a resorbable collagen membrane (Bio-Gide®). At the test sites, the xenogenic bone substitute mineral was coated with rhBMP-2 in a lyophilization process. Following implant insertion (baseline), the peri-implant bone defect height was measured from the implant shoulder to the first implant–bone contact. After an average healing period of 6 months (SD 0.17, range 5.7–6.2), the residual defects were again measured and trephine burs were used to take 22 bone biopsies from the augmented regions. The healing period was uneventful except for one implant site that showed a wound dehiscence, which spontaneously closed after 4 weeks. Later at reentry, all implants were stable. At baseline, the mean defect height was 7.0 mm (SD 2.67, range 3–12 mm) at test and 5.8 mm (SD 1.81, range 3–8 mm) at control sites. At reentry, the mean defect height decreased to 0.2 mm (SD 0.35, range 0–1 mm) at test sites (corresponding to 96% vertical defect fill) and to 0.4 mm (SD 0.66, range 0–2 mm) at the control site (vertical defect fill of 91%). Reduction in defect height from baseline to reentry for both test and control sites was statistically significant (Wilcoxon P〈0.01). Histomorphometric analysis showed an average area density of 37% (SD 11.2, range 23–51%) newly formed bone at test sites and 30% (SD 8.9, range 18–43%) at control sites. The fraction of mineralized bone identified as mature lamellar bone amounted to 76% (SD 14.4, range 47.8–94%) at test compared to 56% (SD 18.3, range 31.6–91.4%) at control sites (paired t-test P〈0.05). At BMP-treated sites 57% (SD 16.2, range 29–81%) and at control sites 30% (SD 22.6, range 0–66%) of the surface of the bone substitute particles were in direct contact with newly formed bone (paired t-test P〈0.05). It is concluded that the combination of the xenogenic bone substitute mineral with rhBMP-2 can enhance the maturation process of bone regeneration and can increase the graft to bone contact in humans. rhBMP-2 has the potential to predictably improve and accelerate guided bone regeneration therapy.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1600-051X
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: The aim of the present systematic review was to assess the survival of implants in regenerated bone applying the method of guided bone regeneration (GBR) compared with the survival of implants in non-regenerated bone. Studies to be included in this review needed to provide at least 12-month results following prosthetic reconstruction of titanium implants in bone regenerated by GBR with or without membrane supporting materials. The outcome measures were implant survival described as presence of implant, implant success (according to the criteria in the respective study), absence of clinical implant mobility, absence of implant fracture, absence of progressive peri-implant crestal bone loss as assessed on radiographs without clinical signs of peri-implant infection, absence of peri-implant infection with suppuration. A MEDLINE search and a hand search of relevant scientific journals were conducted including studies from the year 1990 to May 2001. A total of 11 studies could be identified fulfilling the inclusion criteria. All studies except two had the characteristics of case series or cross-sectional surveys. The two different studies had both test and control implants included in their analysis and qualified as controlled clinical trials. Cumulative success or survival rates, respectively, for implants in regenerated bone ranged from 100% after 5 years to 79.4% after 5 years of function. Regarding survival data, no significant differences were found in the controlled clinical trials between implants in regenerated compared to implants in non-regenerated bone. Within the limits of this systematic review characterized by second and third levels of evidence, the following conclusions can be drawn: The survival rate of implants placed into sites with regenerated/augmented bone using barrier membranes varied between 79% and 100% with the majority of studies indicating more than 90% after at least one year of function. The survival rates obtained in the present systematic review are similar to those generally reported for implants placed conventionally into sites without the need for bone augmentation.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...